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ABSTRACT  
Background: Factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) are 
associated with risk of arterial and venous thrombosis and with hemorrhagic disorders. We 
aimed to identify and functionally test novel genetic associations regulating plasma FVIII and 
VWF.  
Methods: We meta-analyzed genome-wide association results from 46,354 individuals 
of European, African, East Asian, and Hispanic ancestry. All studies performed linear regression 
analysis using an additive genetic model and associated approximately 35 million imputed 
variants with natural-log transformed phenotype levels. In vitro gene silencing in cultured 
endothelial cells was performed for candidate genes to provide additional evidence on 
association and function. Two-sample Mendelian randomization (MR) analyses were applied to 
test the causal role of FVIII and VWF plasma levels on the risk of arterial and venous thrombotic 
events.  
Results: We identified 13 novel genome-wide significant (p≤2.5x10-8) associations; 7 with FVIII 
levels (FCHO2/TMEM171/TNPO1, HLA, SOX17/RP1, LINC00583/NFIB, RAB5C-KAT2A, 
RPL3/TAB1/SYNGR1, and ARSA) and 11 with VWF levels (PDHB/PXK/KCTD6, SLC39A8, 
FCHO2/TMEM171/TNPO1, HLA, GIMAP7/GIMAP4, OR13C5/NIPSNAP, DAB2IP, C2CD4B, 
RAB5C-KAT2A, TAB1/SYNGR1, and ARSA), beyond 10 previously reported associations with 
these phenotypes. Functional validation provided further evidence of association for all loci on 
VWF except ARSA and DAB2IP. MR suggested causal effects of plasma FVIII activity levels on 
venous thrombosis and coronary artery disease risk and plasma VWF levels on ischemic stroke 
risk.  
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Conclusions: The meta-analysis identified 13 novel genetic loci regulating FVIII and VWF 
plasma levels, 10 of which we validated functionally. We provide some evidence for a causal 
role of these proteins in thrombotic events.  
Keywords: Genetic, Association Studies, GWAS, Cardiovascular Disease, Risk Factors, FVIII, 
VWF 
CLINICAL PERSPECTIVE 
What is new?  
• Plasma coagulation factor VIII (FVIII) and von Willebrand factor (VWF) concentrations are 
associated with risk of cardiovascular disease, but the factors that control their levels are not 
fully understood.   
• Using a multi-ethnic meta-analysis of genome wide association studies, we identified 7 
genome-wide significant novel associations for FVIII and 11 for VWF. 
What are the clinical implications? 
• We evaluated the effect of genetic variants with coronary artery disease, ischemic stroke, and 
venous thrombosis through Mendelian randomization analyses and found evidence of a 
causal effect of FVIII activity levels on venous thrombosis and coronary artery disease risk, 
and a causal effect of plasma VWF levels on stroke risk.  
• Our findings suggest that FVIII and VWF may be potential therapeutic targets to prevent 
thrombotic events.   
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INTRODUCTION 
Factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) regulate hemostasis and 
thrombosis, and higher plasma levels of these factors have been associated with risk of arterial 
and venous thrombosis, while lower levels are associated with hemorrhagic disorders1-4and with 
reduced risk of thrombotic events 5. Previously published genetic association studies have 
investigated the contribution of nucleotide variation to plasma levels of these factors using 
genome-wide and exome-wide markers6-8. These studies identified and replicated 8 genetic loci 
associated with plasma VWF levels (STXBP5, SCARA5, ABO, STAB2, STX2, VWF, TCN2 and 
CLEC4M), 5 of which were also associated with FVIII levels (STXBP5, SCARA5, ABO, STAB2, 
and VWF). These discoveries have broadened our understanding of the regulation of hemostasis 
through follow-up functional investigations9, 10. 
 
The causal effect of these factors on bleeding is well-established, since severe FVIII and VWF 
deficiencies lead to bleeding disorders hemophilia A and von Willebrand disease, respectively. 
While it is currently unclear whether FVIII and VWF levels causally influence the risk of 
thrombotic diseases, some genetic and observational evidence point towards an effect of these 
proteins on thrombotic disease. Genetic variants in F8 gene and in 3 VWF-associated genes 
(ABO, STXBP5 and VWF) are robustly associated with risk of venous thrombosis but no causal 
association has been established11-13.  
 
The aim of this investigation was to identify new genetic associations that influence plasma 
levels of FVIII and VWF by expanding the size and ancestral diversity of the discovery sample 
from previous genome-wide association studies (GWAS) and by improving coverage of the 
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genome through the use of 1000 Genomes imputed data and the inclusion of chromosome X 
variants14. For discoveries that reached genome-wide significance, we conducted first-pass 
functional characterization of the candidate loci both to provide additional evidence of 
association and to better understand the biology regulating plasma levels of these coagulation 
phenotypes. Last, by applying our genetic findings as instrument variables, we characterized the 
causal effect of plasma FVIII and VWF levels on clinical cardiovascular (CV) events using 
Mendelian randomization (MR) analyses. 
 
METHODS 
Due to patient confidentiality agreements and to comply with the study participants consent, the 
original data and study materials cannot be made available to other researchers for purposes of 
reproducing the results or replicating the procedure. Analytic methods will be made available 
upon request, and summary statistics have been made publicly available through dbGaP. 
 
Study Design and Participating Cohorts 
This project was organized within the Cohorts of Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium Hemostasis Working Group15. We meta-analyzed 
phenotype-genotype associations of low-frequency and common (minor allele frequency [MAF] 
> 0.01) variants in 32,610 individuals from 9 studies with FVIII levels, and in 46,354 individuals 
from 18 studies with VWF levels. A total of 20 studies contributed to one or both of the 
analyses; these included participants of European (EUR), African (AFR), East Asian (ASI), and 
Hispanic (HIS) ancestry. Descriptions and ancestry composition of participating cohorts are 
found in Supplementary Table S1. All studies were approved by appropriate institutional review 
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committees and all participants gave written informed consent for themselves and their minor 
children for the use of their DNA. 
 
Study-Level Methods 
Genotype Calling and Quality Control 
All participating cohorts performed genotyping using commercial genotyping platforms 
available from Illumina or Affymetrix. Each study performed genotyping quality control checks 
and imputed the approximately 35 million polymorphic autosomal and X-chromosome variants 
described in the 1000 Genomes population phase 1 version 3 for each participant using available 
imputation methods16. Variant calling and quality control procedures for each cohort are 
described in Supplementary Table S1. 
 
Statistical Analyses 
Association Analyses 
Plasma FVIII activity or VWF antigen levels were measured in all participants and reported in % 
or IU/ml*100 units. Participants with plasma FVIII or VWF levels (or activity levels) 3-
standard-deviations above or below the population mean were removed, as were individuals on 
anticoagulation therapy. Natural-log transformed FVIII activity and VWF antigen levels (% or 
IU/ml*100 units) were analyzed separately within each study. Study-specific regression analyses 
using an additive model of inheritance were performed for imputed variant dosages and 
phenotype levels, adjusting for sex, age, study design variables, and population substructure 
using principal components. All analyses were stratified by ancestry and then meta-analyzed. X-
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chromosome variants were additionally stratified by sex, with dosage values for males coded as 
0/2. 
Quality Control 
Study-specific findings were uploaded centrally and a quality control (QC) pipeline of all 
individual studies prior to meta-analysis was conducted using the EasyQC software package17. 
Variants with beta or standard errors (SE) values > 5 or imputation values < 0.3 were excluded 
from the analysis. Estimated minor allele counts (eMAC) calculated for all SNPs were a function 
of allele frequency, total number of samples per cohort, and imputation quality; values <10 were 
excluded from analysis. Alleles were harmonized according to 1000 Genomes phase1 version3 
reference panel and duplicated SNPs or SNPs that had inconsistencies with the reference were 
excluded. 
 
Meta, Trans-Ethnic, and Multi-Phenotype Discovery Analyses 
Meta-analyses were performed in METAL within each ancestry group using a fixed-effects 
inverse-variance weighted approach then combined in a trans-ethnic analysis using the same 
method18. The trans-ethnic analyses are presented as discovery results and we used the ancestry-
specific analyses to inform and interpret these signals. An association was considered genome-
wide statistically significant at p-value <2.5x10-8 to correct for the low-frequency variants that 
were not included in the initial generation of GWAS19 and only variants that passed QC in at 
least 3 cohorts were reported. Variants with MAF below 1% were filtered out after the meta-
analyses. A genomic control coefficient was computed for each discovery cohort and was used to 
correct for cryptic relatedness. Finally, a locus was defined as +/- 1Mb from the SNP with the 
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lowest p-value, and the SNP with the lowest p-value was selected to represent the locus. Multi-
phenotype methods are described in Supplementary Methods. 
 
Functional Characterization of Candidate Loci through Gene Silencing 
In the absence of replication cohorts, we conducted first-pass functional characterization of the 
candidate loci to provide additional evidence of association. For each genome-wide significant 
locus, we selected candidate genes that could be responsible for the observed associations. 
Selection was based on proximity to the most associated SNPs in each region, information from 
public databases on putative effect of the SNPs in terms of regulation of expression and function 
of nearby genes, and hypothesis for a biological mechanism to regulate VWF/FVIII. This 
selection process identified 1 to 3 candidate genes for each associated locus. To screen for 
functionality, human umbilical vein endothelial cells (HUVEC; Life Line Cell Technology) were 
plated on collagen coated 96-well plates and transfected with siRNA (Silencer Select, 
ThermoFisher Scientific) directed against the candidate genes using the transfection reagent 
oligofectamine (ThermoFisher Scientific). Cells were cultured for 4 days after transfection, and 
media was then replaced with control media or media containing 10 µM of histamine for 30 
minutes, to stimulate an inflammatory response. The FVIII and VWF in the media was measured 
by an ELISA using antibodies from Fitzgerald Industries and had detection ranges of 0.003-0.21 
IU/ml for the FVIII assay and 0.5-120 ng/ul for the VWF assay. Every experiment was repeated 
4 times and results are expressed as the mean ± standard deviation (SD) of relative expression 
compared with a negative control (transfected with scramble siRNA). 
 
Follow-up Genetic Analyses 
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Conditional Analyses 
To identify additional independent genetic signals at the associated loci, we used an approximate 
method implemented in GCTA for conditional and joint analysis using meta-analysis summary 
statistics20. We used best-guess imputation for variants with imputation quality >0.3 in 8,481 
European-ancestry individuals from the Framingham Heart Study (FHS) as the reference panel. 
A description of the FHS is given in the Supplementary Methods. In order to prevent spurious 
conditional associations arising from a discrepancy between linkage disequilibrium in our 
GWAS and the reference panel, we also performed the conditional analysis on the results of the 
European-ancestry meta-analysis as a sensitivity analysis, since different genetic variants showed 
the strongest association in the trans-ethnic analysis compared with the European-only analysis. 
 
Mendelian Randomization 
For the sentinel variant in each locus in FVIII and VWF analyses, we conducted in silico lookups 
for the associations of each individual variant with 3 major CV events: coronary artery disease 
(CAD) in the CARDIOGRAMplusC4D Consortium21, 22, ischemic stroke (IS) in the 
MEGASTROKE analysis within the International Stroke Genetics Consortium23, and venous 
thromboembolism (VTE) in the International Network on Venous Thrombosis (INVENT) 
Consortium11. We conducted 2-sample Mendelian Randomization (MR) analyses to detect any 
potential causal effects of plasma FVIII and VWF levels on each CV outcome, separately. We 
used summary statistics to generate 1 causal estimate per significant locus as the ratio of the 
variant’s association with disease to the variant’s association with the exposure, and estimates 
were then meta-analyzed using an inverse-variance weighted approach as our primary MR 
estimate, known as the inverse-variance weighted (IVW) estimate24. Additional methods to avoid 
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bias due to heterogeneity, and the final variants composing the instrumental variables are further 
described in Supplementary Methods and in Supplementary Tables S2, S3, and S4. Since FVIII 
plasma levels are largely determined by VWF plasma levels owing to VWF’s carrier role for 
FVIII in plasma, essentially all genetic predictors of plasma VWF levels are also predictors of 
FVIII plasma levels. The inverse, however is not true, and a small subset of variants predict 
FVIII plasma levels without predicting VWF levels. To investigate the independent causal role 
of FVIII plasma levels from that of VWF plasma levels on CVD events, we applied a 
multivariable MR (MVMR) approach where we adjusted for VWF variants effects in the 
estimate of causal association between FVIII and CVD outcomes25.  
 
RESULTS  
FVIII, VWF, and Multi-phenotype Meta-Analyses 
Agnostic Discovery 
Data used for FVIII meta-analysis was available from 25,897 European (EA), 4,500 African 
(AA), 773 East or Indian Asian (EAA, IAA), and 1,440 Hispanic (HA) participants. Trans-ethnic 
meta-analysis for FVIII resulted 13,887,196 variants passing all filters, and identified 1,431 
variants that reached genome-wide statistical significance at 11 loci. Data used for VWF was 
available from 42,379 EA, 3,700 AA, and 275 HA participants. Meta-analysis for VWF resulted 
in 10,537,485 variants passing all filters, and identified 2,453 genome-wide significant variants 
at 17 loci (Figures 1A-B). European-specific meta-analysis identified one significant variant at 
one additional locus. Analysis using combined FVIII and VWF phenotypes (see Supplementary 
Methods) identified 2,828 variants reaching genome-wide significance at 2 additional loci, which 
were not identified in single-phenotype analyses.  
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Table 1 shows the genetic discovery results for the FVIII, VWF, and combined FVIII-VWF 
phenotypes. Overall, 23 unique loci were identified. Among these, 13 were new associations not 
previously reported. Among the newly identified loci, 7 were associated with FVIII levels 
(FCHO2/TMEM171/TNPO1, HLA, SOX17/RP1, LINC00583/NFIB, RAB5C/KAT2A, 
RPL3/TAB1/SYNGR1/PDGB, and ARSA) and 11 were associated with VWF levels 
(PDHB/PXK/KCTD6, SLC39A8, FCHO2/TMEM171/TNPO1, HLA, GIMAP7/GIMAP4, 
OR13C5/NIPSNAP, DAB2IP, C2CD4B, RAB5C/KAT2A, RPL3/TAB1/SYNGR1/PDGB, and 
ARSA). Supplementary Figures S1a-n shows regional plots for the novel loci plotted for the 2 
phenotypes. The lowest MAF for the index variant was 0.02 while the effect size per allele 
ranged from 0.015 to 0.032 (in log transformed units) for FVIII levels and from 0.014 to 0.060 
for VWF levels. 
 
Among the 23 genome-wide significant findings, 10 loci were previously reported to be 
associated with plasma levels of FVIII or VWF or both: STXBP5, SCARA5, ABO, ST3GAL4, 
STAB2, STX2, VWF, TCN2, CLEC4M, and TMLHE-F8 region.  
 
Conditional Analyses and Variant Characterization 
In follow-up analyses, we conditioned on sentinel variants to determine if secondary independent 
genome-wide significant signals were present. Results and additional independent variants are 
summarized in Table 2 along with findings from in silico investigations of the putative functional 
variant, and in Supplementary Tables S5 and S6. SCARA5, ABO, VWF and STAB2 were 
predicted to have more than one independent signal both for FVIII and VWF analyses (details in 
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Supplementary Methods and in Supplementary Tables S5 and S6), some of which are in 
agreement with previous publications6. Among the independently associated variants within the 
ABO locus, SNPs rs10901252 and rs687621 perfectly discriminate B and O blood groups from 
A, and rs8176685 can reasonably capture information to tag A1/A2 (r2 0.59/D’ 0.99 with the tag 
SNP), confirming that ABO blood groups are essential determinants of VWF and FVIII plasma 
levels. 
 
Variance Explained 
Overall, the top variants for these loci (including the strongest independent associated variants in 
each locus that reached genome-wide significance after conditional analyses) explain 17% of the 
phenotypic variance for FVIII and 21.3% of the variance for VWF.  ABO locus was by far the 
strongest determinant, alone explaining 13.6% and 16.2% of these variances, respectively. 
 
Functional Analyses 
We silenced 21 genes across 12 loci to assess the in vitro impact on FVIII and VWF secretion 
(Figures 2a-b). These include the main candidate genes identified by proximity (Table 1). Our 
results suggest that 10 of the 12 candidate loci had one or more genes that changed VWF levels 
in media under basal and/or histamine-stimulated conditions. Specifically, silencing PDHB, 
SLC39A8, TMEM171, TNPO1, HLA-C, GIMAP7, NIPSNAP3A, NIPSNAP3B, C2CD4B, and 
SYNGR1 increased VWF release into media under basal conditions whereas ST3GAL4 silencing 
decreased VWF secretion. When cells were stimulated with histamine, silencing TMEM171, 
TNPO1, HLA-C, SNIPSNAP3A (but not SNIPSNAP3B), C2CD4B, KAT2A, and TAB1 increased 
VWF release in the media, and RAB5C decreased VWF secretion (Table 1; Figures 2a-b). For 
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the experiments on the 5 genes that were only shown to be associated with FVIII levels 
(LINC00583, NFIB, SOX17, RP1 and TMLHE-F8), we could not find detectable levels of FVIII 
in media from treated HUVEC cells, and therefore the experiments were inconclusive. 
 
Mendelian Randomization Analyses and Cardiovascular Events 
Figure 3 show forest plots representing the results from MR analyses. We first analyzed FVIII 
and VWF individually using the IVW estimates that included the sentinel variant in each locus 
(after exclusion of variants with pleiotropic effects, see Supplementary Tables S2, S3, and S4). 
Both VWF and FVIII plasma levels showed a significant causal effect on CAD, IS and VTE risk. 
For CAD, the ORs associated with a per SD change in natural log-transformed FVIII and VWF 
were (OR(CI95) =1.15 (1.05, 1.27) and 1.14 (1.05, 1.23), respectively. For IS, the ORs(CI95) were 
1.28 (1.14, 1.43) and 1.19 (1.10, 1.29), respectively. For VTE, the ORs(CI95) were 2.75 (2.14, 
3.55) and 2.31 (1.89, 2.81), respectively. Sensitivity analyses using both MR-Egger regression 
and weighted median estimates support the IVW estimates and no significant pleiotropic effect 
was evident after exclusion of the pleiotropic loci (Figure 3, Supplementary Table S3, 
Supplementary Figures S2a-c). 
 
We then performed MVMR analyses of the FVIII phenotype to identify causal effects of FVIII 
activity levels independent of VWF levels. For VTE and CAD outcomes, adjustment of FVIII 
results by the effect of VWF, the ORs were modestly attenuated (20% and 16% respectively) 
compared with the unadjusted estimates and confidence intervals widened. For IS, however, 
adjustment of FVIII results by the effect of VWF resulted in an 86% attenuation of the OR(CI95) 
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to 0.88 (0.51, 1.51). We could not demonstrate a causal association of VWF levels with VTE and 
CAD independent of FVIII levels.  
 
Of note, both the ABO and HLA loci were excluded from the instrumental variables for the MR 
analyses due to evidence of pleiotropic effects shown in the heterogeneity tests (Supplementary 
Table S3). When we estimated causal effects using ABO alone as an instrument, estimates of 
causal effects were essentially the same across phenotypes and outcomes: OR(CI95) 2.57 (2.47-
2.67) for FVIII and VTE; OR(CI95) 2.28 (2.18-2.38) for VWF and VTE; OR(CI95) 1.10 (1.06-
1.14) for FVIII and IS; OR(CI95) 1.09 (1.05-1.13) for VWF and IS; OR(CI95) 1.10 (1.06-1.14) for 
FVIII and CAD; and OR(CI95) 1.08 (1.04-1.12) for VWF and CAD.  
 
DISCUSSION  
In the present study, we meta-analyzed data from more than 36,000 individuals with FVIII levels 
and more than 46,000 with VWF and identified 13 novel loci, 7 of which associated with FVIII 
plasma levels and 11 associated with VWF levels. Overall, new discoveries yielded an additional 
6.2% and 8.1% proportion of variance explained for FVIII and VWF respectively from previous 
estimations8, and suggest that a great proportion of the genetic variance is explained by common 
variation.  Further, we presented experimental evidence of biological function on VWF 
regulation for 14 of these genes from gene silencing in vitro: PDHB, SLC39A8, TMEM171, 
TNPO1, HLA-C, GIMAP7, NIPSNAP3A and B, ST3GAL4, C2CD4B, RAB5C, KAT2A, TAB1, 
SYNGR1. Last, we provide evidence in support of a causal role of FVIII levels on VTE and CAD 
events and of VWF levels on IS events. 
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Characterization of the Novel Loci Regulating FVIII and VWF 
As expected for traits with strong genetic correlation, most of the newly associated loci 
regulate both FVIII and VWF levels in blood. Our results show that most of the highest-
signal independent variants associated with these traits were located in introns or non-coding 
regions, although a substantial proportion were in strong LD (R2>0.8) with mutations 
causing missense or frameshift mutations in the nearby genes (Table 2 and Supplementary 
Table S7). We also explored eQTL associations using publicly available data and we 
conducted pathway analyses for the novel loci. See Supplementary Methods and 
Supplementary Tables S8-S13 for this information. 
 
For most loci, several genes were identified within the associated region, and we selected 1 
or more genes for further characterization using in vitro cell models. Based on our initial 
functional characterization, 1 or more plausible culprit genes regulating VWF secretion 
could be isolated at most loci. Interestingly, several candidate genes that showed a clear 
change in VWF levels upon silencing have been shown to participate in vesicle trafficking 
and exocytosis, as well as intracellular signaling and inflammatory response. The most 
relevant functional genes are described below and summarized in Supplementary Figure S3. 
 
VWF Biogenesis, Vesicle Trafficking and Secretion 
ST3GAL4 is a Golgi transferase that catalyzes transfer of sialic acids in VWF glycan 
branches that are essential to its biogenesis, adhesive activity and clearance26. It also has a 
role in clearance of desialylated platelets with effects on platelet homeostasis. Genetic 
variants in ST3GAL4 locus have been associated with total cholesterol, LDL cholesterol, 
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alkaline phosphatase, increased platelet aggregation, fibrinogen, CRP, and CAD (see further 
details and references in Supplementary Table S7). Our functional analyses showed a 
substantial reduction of VWF release upon ST3GAL4 silencing, which strengthens the 
evidence of this gene as a novel VWF regulator in basal conditions.  
 
SYNGR1 (Synaptogryn-1) encodes an integral membrane protein associated with presynaptic 
vesicles in neuronal cells. Several commonalities have been described between the exocytic 
machinery that drives vesicle trafficking and membrane fusion in endothelial cells and 
synaptic machinery found in neurons 27, 28, which suggest that SYNGR1 could have a role in 
vesicle trafficking and exocytosis of VWF from the Weibel-Palade bodies. Genetic variation 
in this locus has also been associated with IgG glycosylation, rheumatoid arthritis, and 
inflammatory bowel disease/Crohn’s disease, the last 2 consistent with an effect of 
deregulation of interleukin and inflammatory signaling pathways. 
 
NIPSNAP3A and NIPSNAP3B were selected as the main biologically plausible genes for 
locus on chromosome 9, and results from the functional study show evidence of significant 
upregulated levels of VWF upon silencing of either gene. Again, a reported role of these 
genes in vesicular trafficking29 suggest that these genes could be important in Weibel-Palade 
formation and exocytosis of VWF, both in basal conditions and under inflammatory stimuli.  
 
Among the 2 new loci found in the trans-ethnic multi-phenotype analysis, RAB5C is 
particularly interesting. It is a member of the Rab protein family, thought to ensure fidelity 
in the process of docking and fusion of vesicles with their correct acceptor compartment30, 
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which may be relevant to the process of fusion of Weibel-Palate vesicles to release VWF in 
endothelial cells. RAB5C silencing caused a significant decrease of VWF release in media of 
endothelial cells upon stimulation with histamine.  
 
Our in vitro cell work showed a significantly increased VWF secretion upon PDHB 
silencing. PDHB codes for a subunit of the pyruvate dehydrogenase complex, which 
converts pyruvate to acetyl-CoA in the mitochondrion. We speculate that it is possible that 
the metabolism of endothelial cells regulates vesicle trafficking and exocytosis of VWF, 
meaning that the exocytosis process is dependent on the energetic status of the endothelial 
cell. Genetic variation in this locus has also been associated with total cholesterol, SLE, and 
RA. 
 
Intracellular Signaling and Inflammatory Response 
TAB1 silencing increased VWF released in media in our in vitro functional analyses, 
whereas no effect could be seen for PDGFB, a gene that has been implicated in CAD and 
VTE risk. TAB1 is a regulatory protein that acts as a mediator of several intracellular 
signaling pathways, especially those mediated by TGF-ß, WNT-1 and interleukin-1 which 
suggest it might have a role mediating VWF release upon certain cellular stimuli.  
 
Similarly, silencing C2CD4B gene in cultured endothelial cells resulted in strong 
upregulation of VWF release both in basal and under stimulus conditions. Allelic variants in 
this gene have also been associated with fasting glucose homeostasis and type 2 diabetes. 
Transcripts of this gene are predominantly found in the nuclear compartment of endothelial 
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cells, and a possible role in regulation of transcription that might increase vascular 
permeability in acute inflammation has been suggested31. Similarly, TNPO1 codes for a 
nuclear receptor (Transportin-132) which mediates nuclear import of several proteins, which 
could also suggest a role in regulation of transcription under certain circumstances. 
 
DAB2IP is involved in several relevant cell-signaling pathways in response to inflammation, 
innate immune response, and cell growth inhibition, apoptosis, cell survival, angiogenesis, 
cell migration and maturation in endothelial cells, and genetic variation in this gene has been 
associated with abdominal aortic aneurysm and heart rate. Despite the strong genetic signal 
in our data, functional confirmation could not be achieved for DAB2IP in our secretion 
experiment so additional investigative work is needed.  
 
GIMAP7 showed a significant increase of VWF release upon silencing. GTPases of 
immunity-associated proteins (GIMAPs) are regulators of lymphocyte survival and 
homeostasis 33 although limited data have been published regarding the function of these 
proteins.   
 
Finally, although it did not reach genome-wide significance in the trans-ethnic meta-
analysis, we found a single locus that close to SLC39A8 and that was genome-wide 
significant in our meta-analysis VWF associations in European-ancestry samples. This gene, 
which encodes a zinc transporter that functions in the cellular import of zinc at the onset of 
inflammation, has also been associated with blood pressure, high-density lipoprotein (HDL) 
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cholesterol levels and BMI. Our functional work also suggested a strong effect on VWF 
levels in media from endothelial cells in vitro upon SLC39A8 silencing. 
 
Although further functional characterization of these genes is needed to fully characterize the 
role of all the investigated genes in VWF regulation, our results demonstrate that these studies 
are a valid tool to elucidate functional genes coming from genetic associations, and to shed light 
into the most relevant biological pathways implicated in the regulation of the phenotype under 
study. 
 
Mendelian Randomization and Clinical Implications 
Our results provide insights into the causal role of FVIII and VWF in 3 CV events, which are the 
leading causes of deaths globally.  
 
Biological and genetic evidence indicate that circulating FVIII levels are mainly determined by 
levels of VWF34. In the present study, we calculated the genetic correlation between VWF and 
FVIII based on the genome-wide association results from European-descent individuals (see 
Supplementary Methods) and found that the proportion of shared heritability of between these 2 
phenotypes is 83.5%. This result is strengthened by the overlapping findings found in the 
individual GWAS, and suggests that, with some exceptions, the genetic pathways that regulate 
VWF levels indirectly regulate FVIII levels. Given the role of VWF regulating FVIII, we used 3 
loci that were uniquely associated with FVIII independent of VWF and pursued conditional 
analyses that adjusted for the effect of VWF plasma levels to test the causal effect of FVIII on 
CV events. For IS, we found no evidence of a causal effect of FVIII independent of the VWF 
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effect, which suggests that VWF biology may causally contribute to IS risk. For VTE and CAD, 
however, we found evidence supporting a causal effect of FVIII independent of the VWF effect. 
As there were no genetic loci that independently associated with VWF levels and not FVIII 
levels, we could not adjust the VWF analyses for FVIII. Nonetheless, given the similarities in the 
magnitude of the VWF-adjusted FVIII causal ORs with the VWF causal ORs for VTE and CAD, 
our data suggest that the VWF causal association for VTE and CAD may be driven primarily by 
the biologic effect of FVIII, although this hypothesis could not be tested.  
 
The results of the MR analyses suggest that both FVIII and VWF may be reasonable targets for 
the prevention or intervention of CAD and VTE while VWF may be a reasonable target for IS. 
Indeed over the past decade this line of thinking and research has been pursued and these 
molecules are currently under investigation as pharmaceutical targets for the prevention of 
thrombotic events35-38. In this paper, we report on 23 unique genetic loci associated with plasma 
levels of FVIII and/or VWF, of which 13 are newly reported associations. These discoveries may 
offer new targets in the development of pharmaceutical agonistics or antagonists that may 
modulate thrombotic risk.  
 
Strengths and Limitations 
A major strength of the study was the relatively large sample size and the use of a denser 
imputation panel than was used in past discovery efforts. With this approach, we had hoped to 
identify uncommon associated variants but the MAF of the variants in the newly associated loci 
where relatively common, with just 1 variant having an MAF of less than 0.10. Our study design 
did not identify new associations marked by rare variation. Increasing the number of study 
 22 
participants to increase statistical power or improving the quality of the imputation from 
genotyping arrays may help to identify uncommon or rare variants associated with the outcomes. 
Some of the novel findings may be false positives, as we did not have access to independent 
populations to replicate our discoveries. Replication is required to validate genetic associations, 
especially for those close to the threshold for statistical significance. To offset this limitation, we 
conducted functional validation by silencing candidate genes and measuring VWF release; we 
view this functional work as a strength of the study. We were able to test only the regulation of 
VWF expression and not the regulation of VWF clearance by macrophages39. Nor were we able 
to test other mechanisms that regulates synthesis in megakaryocytes but not endothelial cells. 
Further, the need for a particular cellular stimulus that cannot be mimicked by histamine 
stimulation for the effect to be produced would be missed by our approach. Finally, it could be 
that the effect of some genetic associations can only be seen through overexpression rather than 
silencing of the gene. We attempted to also measure FVIII release but levels were too low so 
new models are required to validate the impact the candidate genes on FVIII levels; this is a 
limitation of our approach. All functional work was done in vitro, which carries limitations 
relative to in vivo investigations. The strong genetic co-regulation of both FVIII and VWF levels 
allowed us to conduct multi-phenotypes analyses and increase statistical power for discovery. 
Our MR approach using improved instrumental variants allows to establish for the first time a 
causal relationship between VWF and FVIII and several CV events. With only 3 loci associated 
with FVIII alone, the power of the VWF-adjusted MR analyses for FVIII and CV events was 
limited and we could not investigate the association of VWF on CV events independent of FVIII. 
There is a degree of overlap between our sample and the sample from consortia providing CV 
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events GWAS data, which might create some bias in MR analyses40; this is a limitation of our 
work. 
 
CONCLUSIONS 
We found 13 novel genetic loci with modest contributions to plasma levels of FVIII and/or 
VWF. Our discovery approach including first-pass functional validation has provided relevant 
information on the best candidate gene at the novel loci. Finally, MR analyses provided some 
evidence implicating FVIII plasma levels in the risk of CAD and VTE, and VWF plasma levels 
in the risk of IS. In summary, our work has identified novel loci regulating proteins essential for 
hemostasis and coagulation. These findings may provide genetic tools for therapeutic and 
preventive strategies and may be useful to identify new biologic pathways upon which to 
intervene to reduce the burden of arterial and venous outcomes.  
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Table 1: Main association results for FVIII and VWF trans-ethnic GWAS meta-analysis.  
 
 1 
 
Footnotes: “Freq” refers to the allele frequency of the effect allele. “B” = baseline; “S” = stimulated; “ns” = not significant; *p-value<0.05; **p-value<0.01; 
***p-value<0.001. 
Beta and Frequency refer always to the Effect_allele, and they are expressed as natural-log transformed values from the original units (reported in % or 
IU/ml*100 units). 
†SLC39A8 was found in vWF meta-analysis of EA only (N=42,145).  
‡ Although not in LD with this variant, a low-frequency variant 665Kb upstream rs9271597 was found significantly associated to vWF levels (rs80082277; 
p=1x10-8) and we consider it within the HLA region; thus, we pursued this gene for further functional validation. 
              
rsID 
Effe
ct  
Alle
le 
Ot
her  
All
ele 
 Freq 
FVIII 
N 
FVIII 
Beta 
FVIII 
P 
FVIII 
Freq 
VWF 
N 
VWF 
Beta 
VWF 
P 
VWF Closest Gene(s) 
Associati
on 
vWF Release at Baseline (B) and upon Stimulation (S) for 
Candidate Loci 
rs55954186 a g 0.36 35,513 0.011 2.2E-05 0.37 46,229 0.015 5.2E-09 PDHB, PXK, KCTD6 New PDHB (B=↑**; S=ns), PXK (B=ns; S=ns), KCTD6 (B=ns; S=ns) 
rs6855246 a g 0.93 35,513 
-
0.003 0.672 0.92 46,068 -0.034 
8.68E-
10 SLC39A8† New SLC39A8 (B=↑**) 
rs548630 a c 0.49 36,286 
-
0.016 2.1E-10 0.47 46,137 -0.018 1.2E-12 
FCHO2, TMEM171, 
TNPO1 New 
FCHO (B=ns; S=ns), TMEM171 (B=↑***; S=↑*), TNPO1 
(B=↑***; S=↑**) 
rs9390460 t c 0.47 36,286 
-
0.019 2.2E-15 0.46 46,212 -0.033 5.6E-42 STXBP5 Known - 
rs9271597 ‡ a t 0.41 28,203 
-
0.015 1.4E-08 0.41 31,364 -0.012 2.1E-04 HLA region New HLA-C (B=↑**;s=↑***) 
rs7788962 a g 0.62 33,773 
-
0.010 2.3E-04 0.61 46,231 -0.014 7.3E-09 GIMAP7, GIMAP4 New GIMAP7 (B=↑***; S=ns), GIMAP4 (B=ns; S=ns) 
rs4276643 t c 0.66 36,286 
-
0.023 1.3E-19 0.67 44,168 -0.029 8.8E-28 SCARA5 Known - 
rs10102164 a g 0.19 36,286 0.019 2.4E-09 0.20 46,230 0.009 2.9E-03 SOX17, RP1 New Too little FVIII released by endothelial cells to be detected in vitro 
rs6479259 t c 0.73 28,535 
-
0.021 1.1E-03 0.73 24,987 -0.056 1.5E-08 OR13C5, NIPSNAP§ New NIPSNAP3A (B=↑*; S=↑**), NIPSNAP3B (B=↑*; S=ns) 
rs10985344 a g 0.25 36,286 0.011 7.5E-05 0.25 46,178 0.017 3.5E-09 DAB2IP New DAB2IP  (B=ns; S=ns) 
rs687289 a g 0.36 36,286 0.145 1.9E-770 0.33 46,231 0.197 
5.0E-
1443 ABO Known - 
9:13930481:
ID d i 0.85 22,480 
-
0.032 2.7E-10 0.85 29,409 -0.003 4.4E-01 LINC00583, NFIB New Too little FVIII released by endothelial cells to be detected in vitro 
rs35458154 a g 0.03 33,871 0.048 3.1E-08 0.03 44,020 0.060 3.0E-12 ST3GAL4 Known || ST3GAL4 (B=↓**; S=ns) 
rs4981022 a g 0.69 36,286 0.025 3.0E-20 0.69 46,232 0.035 6.6E-41 STAB2 Known - 
rs4759787 a c 0.40 36,286 0.011 1.1E-05 0.37 46,180 0.023 7.7E-20 STX2 Known - 
rs2238109 a t 0.39 36,286 0.026 3.5E-24 0.38 46,232 0.050 1.8E-89 VWF Known - 
rs4904820 a g 0.49 36,286 0.014 1.8E-08 0.47 46,232 0.022 6.0E-19 TCN2 Known - 
rs6494314 t c 0.18 36,286 
-
0.007 2.4E-02 0.17 46,232 -0.018 1.1E-08 C2CD4B New C2CD4B (B=↑*; S=↑**) 
rs1869365    Significant in combined multiphenotype analysis <5.0E-8 RAB5C, KAT2A  New RAB5C (B=ns; S=↓*), KAT2A  (B=ns; S=↑**) 
rs2277998 a g 0.30 33,097 
-
0.010 4.4E-04 0.30 45,566 -0.022 6.5E-16 CLEC4M Known - 
rs5750823 # t c 0.70 36,286 
-
0.013 1.5E-06 0.72 46,230 -0.020 6.0E-14 
RPL3, TAB1, SYNGR1, 
PDGB New 
TAB1 (B=ns; S=↑**), SYNGR1 (B=↑*; S=ns), PDGFB (B=ns; 
S=ns) 
rs9616897    Significant in combined multiphenotype analysis <5.0E-8 ARSA New ARSA  (B=ns; S=ns) 
rs150926226 
¶ c g 0.62 20,537 0.017 3.3E-09 0.65 28,685 -0.005 7.0E-02 TMLHE, F8 Known Too little FVIII released by endothelial cells to be detected in vitro 
 2 
§Olfactory receptor family was not considered for further functional validation for its low expression in the relevant tissues (mainly artery and whole blood). 
|| The ST3GAL4 locus was new at the time of analyses, although reported in a recent candidate gene study lacking replication (PMID: 27584569). 
# The highest associated SNP in this locus for FVIII is rs137631 (p=9.5x10-9), located close to RPL3 gene, 112Kb downstream TAB1/SYNGR1 locus and in 
low LD with rs5750823 (R2=0.14) 
¶ Chromosome X variant for VWF only available for EU samples (N=28.685). 
 
 
Table 2: Characteristics of all associated independent variants after conditional analyses. 
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MarkerName rsID Closest Gene(s) variant position 
 
 
 
 
putative functional 
EUR-only 
TRANS-
ethnic 
Top Meta 
variant LD† (r2) 
LD* (D') Original P-value 
Conditional 
P-value 
Original P-
value 
Conditio
nal P-
value 
  
FVIII (n=29,573 EUR; n=36,286 TRANS) 
5:72406659 rs548630 
TNPO1; FCHO2; 
TMEM171 9.5 kb 5' TMEM171 
  
5.14E-10 3.96E-10 2.10E-10 2.06E-10 5:72406659 Top variant Top variant 
6:147701217 rs9390461 STXBP5 intronic rs1039084, missense 2.74E-13 4.06E-13 1.73E-14 - 6:147703299 0.98 1.00 
6:147703299 rs9399599 STXBP5 intronic rs1039084, missense 3.73E-13 - 1.41E-15 4.70E-16 6:147703299 Top variant Top variant 
8:27778148 rs55829013 SCARA5 intronic   3.39E-10 8.54E-10 5.81E-10 - 8:27805815 0.51 0.77 
8:27823832 rs11780263 SCARA5 intronic   3.41E-17 6.96E-17 1.39E-19 - 8:27805815 0.10 0.98 
8:27805815 rs7816579 SCARA5 intronic SiPhy conserved 5.32E-16 - 6.52E-21 4.07E-21 8:27805815 Top variant Top variant 
8:55421614 rs10102164 SOX17; RP1 intergenic   1.66E-07 - 2.38E-09 2.44E-09 8:55421614 Top variant Top variant 
9:13930481:ID rs35468074 LINC00583 intronic   1.74E-10 1.24E-10 2.66E-10 3.10E-10 9:13930481:ID Top variant Top variant 
9:136116662 rs11793768 ABO 14 Kb 3' ABO   3.74E-13 1.29E-62 2.16E-13 - 9:136132908:ID 0.08 0.72 
9:136137065 rs687621 ABO intronic   1.18E-647 p<1E-320 6.85E-778 - 9:136132908:ID 0.89 0.98 
9:135976698 rs35108384 ABO intronic   4.58E-12 - 2.24E-12 6.53E-12 9:136132908:ID 0.00 0.14 
9:136114000 rs78490142 ABO 17 kb 3' ABO   1.12E-03 - 6.53E-05 1.48E-13 9:136132908:ID 0.01 1.00 
9:136132908:ID rs8176719 ABO intronic 
SiPhy conserved 
1.62E-307 - 3.52E-403 
p<1E-
320 9:136132908:ID Top variant Top variant 
9:136178821 rs574237 ABO intergenic   2.89E-29 - 6.94E-38 5.38E-26 9:136132908:ID 0.01 0.18 
9:136181539 rs551924 ABO intergenic   2.81E-48 - 9.21E-75 2.20E-63 9:136132908:ID 0.00 0.14 
9:136207218 rs607900 ABO intergenic 
rs116779216, 
missense SURF1 6.86E-03 - 3.21E-15 1.85E-13 9:136132908:ID 0.00 0.19 
9:136255149 rs62575992 ABO intergenic   3.46E-42 - 8.45E-45 1.83E-26 9:136132908:ID 0.02 0.80 
9:136344853 rs3124758 ABO intergenic   2.71E-21 - 1.74E-18 5.88E-15 9:136132908:ID 0.00 0.14 
12:6062894 rs57040304 VWF intronic 
rs7962217, missense, 
SiPhy cons 1.51E-15 1.22E-14 7.71E-12 - 12:6160614 0.00 0.09 
 4 
12:6160614 rs7135039 VWF intronic rs1063856, missense 3.00E-19 7.02E-18 2.32E-24 7.21E-20 12:6160614 Top variant Top variant 
12:6070845 rs12423482 VWF intronic 
rs7962217, missense, 
SiPhy cons 2.49E-15 - 2.92E-18 1.57E-17 12:6160614 0.00 0.15 
12:6160146 rs11064010 VWF intronic   8.36E-07 - 2.41E-11 2.51E-09 12:6160614 0.01 0.33 
12:104000319 rs1070073 STAB2 intronic   1.07E-13 5.04E-13 2.25E-14 - 12:104149874 0.00 0.16 
12:104147207 rs3751198 STAB2 intronic   2.16E-17 5.91E-17 5.88E-18 - 12:104149874 0.70 0.98 
12:104000470 rs2723889 STAB2 intronic   1.08E-13 - 2.14E-14 1.21E-14 12:104149874 0.00 0.16 
12:104149874 rs4981022 STAB2 intronic   1.16E-17 - 2.95E-20 4.47E-21 12:104149874 Top variant Top variant 
14:92268531 rs10498631 TC2N intronic   6.69E-09 8.63E-09 2.30E-08 - 14:92302972 0.54 0.82 
14:92302972 rs58204830 TC2N intronic   2.57E-08 - 6.28E-09 7.03E-09 14:92302972 Top variant Top variant 
22:39717706 rs137631 RPL3 1.3Kb 5´of RPL3   2.35E-07 - 9.48E-09 1.34E-08 22:39717706 Top variant Top variant 
X:154721357 rs150926226 TMLHE,F8     
 
‡ 
 
3.25E-09 ‡ 
 
X:154721357 - - 
VWF (n=42,256 EUR; n=46,232 TRANS) 
3:58383174 rs55692656 PXK; KCTD6; PDHB intronic PXK 
rs56384862, missense 
PXK; rs34579268 
missense PXK; 
rs200687616 
frameshift PDHB 
6.48E-09 1.01E-08 3.33E-08 - 3:58436476 0.94 1.00 
3:58436476 rs55954186 PXK; KCTD6; PDHB 17 kb 3´of PXK 
rs56384862, missense 
PXK; rs34579268 
missense PXK; 
rs200687616 
frameshift PDHB 
8.72E-09 - 5.20E-09 8.06E-09 3:58436476 Top variant Top variant 
5:72403453 rs7733340 
TNPO1; FCHO2; 
TMEM171 intergenic 
  
5.80E-13 1.52E-12 3.40E-12 - 5:72406659 0.93 0.99 
5:72406659 rs548630 
TNPO1; FCHO2; 
TMEM171 9.5 kb 5' TMEM171 
  
1.33E-12 - 1.22E-12 6.19E-13 5:72406659 Top variant Top variant 
6:31192766 rs9263993 HLA region intergenic   8.54E-09 3.50E-09 1.69E-07 - 6:31925848 0.00 0.63 
6:31941629 rs116420479 HLA region intronic STK19   3.10E-08 1.49E-08 1.02E-08 - 6:31925848 0.94 0.98 
 5 
6:31158633 rs9263861 HLA region intergenic   3.08E-08 - 3.25E-08 8.64E-09 6:31925848 0.00 1.00 
6:31906828 rs78593564 HLA region intronic C2   3.15E-08 - 1.03E-08 2.76E-09 6:31925848 1.00 1.00 
6:147694334 rs9390460 STXBP5 intronic rs1039084, missense 6.32E-38 1.67E-38 5.58E-42 1.27E-42 6:147694334 Top variant Top variant 
7:150296496 rs13230842 GIMAP7; GIMAP4 intergenic   2.06E-08 1.96E-08 2.95E-08 - 7:150227227 0.18 0.97 
7:150227227 rs7788962 GIMAP7; GIMAP4 
9.1Kb 3´of 
GIMAP7 
  
6.29E-08 - 7.30E-09 1.36E-08 7:150227227 Top variant Top variant 
8:27803599 rs4276643 SCARA5 intronic   5.77E-27 1.19E-29 8.77E-28 7.69E-31 8:27803599 Top variant Top variant 
8:27815481 rs62496810 SCARA5 intronic  3.74E-08 4.38E-11 4.98E-08 6.04E-11 8:27803599 0.02 1 
9:124416940 rs10985344 DAB2IP intronic   4.11E-09 3.76E-09 3.47E-09 - 9:124416940 Top variant Top variant 
9:124421965 rs4837886 DAB2IP intronic   3.84E-09 - 4.43E-09 3.94E-09 9:124416940 0.79 0.97 
9:135919501 rs138796740 ABO intergenic   2.61E-08 7.06E-11 3.59E-08 - 9:136132908:ID 0.00 0.15 
9:136128546 rs7857390 ABO 2.5Kb 3' of ABO   p<1E-320 7.81E-294 2.15E-393 - 9:136132908:ID 0.36 1 
9:136145414:ID rs202001822 ABO intronic   5.90E-78 1.46E-39 2.26E-80 - 9:136132908:ID 0.10 1 
9:136147553 rs660340 ABO intronic   p<1E-320 p<1E-320 1.11E-492 - 9:136132908:ID 0.33 0.87 
9:136177394 rs656105 ABO intergenic   1.20E-66 2.62E-129 4.23E-73 - 9:136132908:ID 0.02 0.19 
9:136128000 rs10901252 ABO 3.1 Kb 3' of ABO 
rs8176747, missense; 
rs8176746, missense; 
rs8176743 missense 
1.78E-291 - 2.61E-351 p<1E-320 9:136132908:ID 0.16 0.99 
9:136130677 rs62641786 ABO 3'UTR   2.79E-96 - 2.59E-106 8.85E-30 9:136132908:ID 0.03 0.91 
9:136138765:ID rs8176685 ABO intronic   p<1E-320 - 5.95E-507 p<1E-320 9:136132908:ID 0.31 1 
9:136316367 rs28680325 ABO intronic ADAMTS13   1.04E-09 - 2.88E-10 1.12E-09 9:136132908:ID 0.01 0.25 
11:126296825 rs35458154 ST3GAL4 intronic  6.35E-12 8.31E-12 2.96E-12 2.42E-12 11:126296825 Top variant Top variant 
12:6157394 rs2283335 VWF intronic rs1063856, missense 6.48E-83 5.55E-79 2.08E-89 - 12:6153967 1 1 
12:6160146 rs11064010 VWF intronic   1.60E-27 8.75E-22 7.90E-27 2.40E-21 12:6153967 0.01 0.30 
12:6225931 rs112814955 VWF intronic   1.43E-42 3.14E-49 9.02E-43 4.00E-50 12:6153967 0.01 0.34 
12:6153967 rs2238109 VWF intronic rs1063856, missense 1.37E-82 - 1.77E-89 3.41E-87 12:6153967 Top variant Top variant 
12:104000319 rs1070073 STAB2 intronic   2.28E-36 8.23E-31 2.03E-36 6.72E-32 12:104149874 0.00 0.16 
12:104007418 rs11111679 STAB2 intronic   2.31E-14 4.79E-10 1.22E-14 1.60E-10 12:104149874 0.00 0.02 
12:104127353 rs73192004 STAB2 intronic rs17034433, missense 2.29E-08 2.33E-08 5.09E-09 6.57E-09 12:104149874 0.01 0.53 
 6 
12:104149874 rs4981022 STAB2 intronic   5.44E-37 4.69E-41 6.57E-41 8.65E-45 12:104149874 Top variant Top variant 
12:131287011 rs6486599 STX2 intronic rs17564, missense 4.23E-18 1.92E-18 1.14E-18 - 12:131290180 1.00 1 
12:131290180 rs4759787 STX2 intronic rs17564, missense 4.45E-18 - 7.73E-20 3.84E-20 12:131290180 Top variant Top variant 
14:92290744 rs10498632 TCN2 intronic   2.58E-18 4.74E-18 5.00E-18 - 14:92318935 0.53 0.99 
14:92318935 rs4904820 TCN2 intronic  8.30E-18 - 6.04E-19 2.40E-19 14:92318935 Top variant Top variant 
15:62455019 rs6494314 C2CD4B 700bp 3´of gene rs8040712, missense 9.63E-08 - 1.14E-08 1.30E-08 15:62455019 Top variant Top variant 
19:7831628 rs2277998 CLEC4M missense rs2277998, missense 2.02E-15 7.30E-16 6.47E-16 1.74E-15 19:7831628 Top variant Top variant 
22:39790191 rs2413590 PFGFB; SYNGR1; TAB1 5.6Kb of TAB1   3.96E-12 4.44E-12 2.02E-12 - 22:39829973 0.75 0.94 
22:39829973 rs5750823 PFGFB; SYNGR1; TAB1 intronic TAB1   2.98E-11 - 5.95E-14 7.58E-14 22:39829973 Top variant Top variant 
 Footnotes: †LD with top variant in the region, calculated using FHS data. ‡Primary SNP was not well imputed in FHS and no other SNPs in the region 
achieved genome-wide significance in conditional analyses. “slct pJ” = joint p-value from GCTA "slct". “Original p-value” = p-value from discovery meta-
analysis. The putative functional column indicates the best candidate variant in high linkage disequilibrium with the associated variant (R2>0.8) that has been 
identified in silico as the best candidate variant to have an impact on the adjacent gene/s. No functional work was performed in known genes, and these are 
symbolized by “-“ in the last column.  
 1 
Figure Legends 
Figure 1A: Manhattan plot for the trans-ethnic analyses FVIII. Representation of genome-
wide results. Loci named by closest gene. In black, novel associations.  
 
Figure 1B: Manhattan plot for the trans-ethnic analyses VWF. Representation of genome-
wide results. Loci named by closest gene. In black, novel associations.  
 
Figure 2A. Silencing candidate genes changes basal release of VWF.    
HUVEC cells were transfected with siRNA against selected genes for 4 days, the media was 
changed, cells were cultured for 30 min, and VWF was measured in the supernatant via ELISA.  
n = 4 ± S.D. *p<0.05, **p<0.01, ***p<0.001. All results are relative to VWF release after 
transfection with a scrambled control siRNA, which is set as reference (100%). 
 
Figure 2B. Silencing candidate genes changes stimulated release of VWF.     
HUVEC cells were transfected with siRNA against selected genes for 4 days, the media was 
changed, cells were stimulated with histamine 10 µM for 30 min, and VWF was measured in the 
supernatant by an ELISA.  n = 4 ± S.D. *p<0.05, **p<0.01, ***p<0.001. All results are relative 
to VWF release after transfection with a scrambled control siRNA, which is set as reference 
(100%). 
 
Figure 3. Mendelian Randomization results. Results show OR (95% confidential interval) per 
every higher standard deviation change in FVIII (Figure 3A) and VWF. (Figure 3B).  CAD 
 2 
(Coronary Artery Disease), IVW(inverse-variance weighted method), IVW.adjusted (IVW FVIII 
adjusted for the effects of VWF). 
